Investigators from more than 200 research institutions worldwide have contributed reagents to the Kerafast program. Researchers find a number of advantages to working with Kerafast, including:
The below case studies illustrate how the program works for some of our participating researchers:
Facilitating Reagent Distribution with Streamlined MTAs and Shipping
Michael A. Whitt, PhD, University of Tennessee; Delta-G-VSV Pseudotyping System
Kerafast enabled a busy lab to fulfill reagent requests with less time and effort through an online MTA and simplified shipping.
Read more >
Bringing a Unique Reagent to Researchers Around the World
Thomas Hollis, PhD, Wake Forest School of Medicine; Protein-Nucleic Acid Complex Crystal Screen
Kerafast spread the word about a unique crystal screen and streamlined the shipping process to bring it to researchers worldwide.
Read more >
Simplifying the Commercialization & Supply of a Reagent in Demand
James H. Morrissey, PhD, University Illinois at Urbana-Champaign; Polyphosphates
Kerafast offered an easy commercialization approach for a lab looking to license its unique and useful reagents.
Read more >
Accelerating the Adoption and Distribution of a Unique Antibody
Scot R. Kimball, PhD, Penn State College of Medicine; Puromycin Antibody and Translation Initiation Factor Antibodies
Kerafast provided a lab with a quick and easy solution to share its novel antibody with the larger scientific community.
Read more >
Streamlining the Worldwide Distribution of Novel Cell Lines
Jaime F. Modiano, VMD, PhD, University of Minnesota, Twin Cities; Canine Cancer Cell Lines
Kerafast enabled a lab to easily outsource its cell line distribution, leading to significant time and money savings.
Read more >